Overview of Ketum

What is Ketum? Defining the Active Ingredient and Class

Property	Description
Active ingredient	Ketoprofen
Form	Capsule, tablet, topical gel, patch
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Pain, inflammation, and fever management
Origin	Synthetic (Propionic Acid Derivative)

Ketum is a trade name for a synthetic, single-ingredient medicine containing the active substance Ketoprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

The drug's core identity stems from Ketoprofen's designation as a propionic acid derivative, placing it among a distinct group of pharmaceuticals engineered to manage inflammatory processes and pain. As a synthetic compound, it is developed in a laboratory setting. Its pharmacological classification includes Ketoprofen as a recognized medicine for managing essential therapeutic needs. Ketoprofen is clinically recognized for its potent analgesic and anti-inflammatory properties, often differentiated from similar NSAIDs by its distinct pharmacokinetic profile.

Composition, Available Forms, and General Purpose

The medication is a single-component product, meaning Ketoprofen is the only therapeutically active substance present, formulated with various inactive excipients.

This single active component is offered in diverse dosage forms to accommodate different patient needs. The available forms include a capsule and tablet for oral administration, and a topical gel, cream, or patch for topical application directly onto the skin. The general purpose of this range of forms is to provide options for either systemic relief (oral) or localized relief (topical), with the overall goal of diminishing discomfort and physical symptoms associated with inflammation. Topical formulations of Ketoprofen are often preferred for conditions where focused, local relief is desired, without relying heavily on systemic absorption.

The Tri-Action Effect of Ketoprofen

The therapeutic benefit of Ketoprofen is the delivery of a tri-action effect, which includes reducing pain, controlling inflammation, and lowering fever.

This combined action is achieved by interfering with the body's chemical pathways that generate pain-signaling compounds. The general benefit is comprehensive relief from symptoms such as swelling, stiffness, and overall aches. This analgesic, anti-inflammatory, and antipyretic effect is central to the drug's utility in conditions characterized by these co-occurring symptoms, providing more than simple pain masking by addressing the underlying inflammatory process itself.

Regulatory References

What side effects are possible with Ketum?

The safety profile of Ketum (ketoprofen) is defined by official regulatory warnings concerning serious risks, particularly those affecting the cardiovascular and gastrointestinal systems. Adherence to usage limitations and monitoring for adverse effects is essential.

Serious Safety Risks

Official regulatory information emphasizes the potential for serious adverse events, which can be fatal. These include:

System-Organ Class	Serious Adverse Reaction Scope
Cardiovascular	Increased risk of serious thrombotic events, including myocardial infarction (heart attack) and stroke. The risk may increase with higher doses and longer duration of use.
Gastrointestinal	Increased risk of bleeding, ulceration, and perforation of the stomach or intestines. These events can occur without warning symptoms.
Dermatologic	Potential for severe and sometimes fatal skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Common and Other Adverse Reactions

Common adverse reactions (those occurring in 1% to 10% of patients) often involve the gastrointestinal system, including dyspepsia, nausea, abdominal pain, and diarrhea. Other reported reactions include headache, dizziness, and somnolence.

Safety Restrictions and Precautions

Contraindications: Use is strictly contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. It is also contraindicated in patients with active peptic ulcer, known hypersensitivity to the drug or other NSAIDs/aspirin, or severe heart, renal, or hepatic impairment.
Population-Specific: Elderly patients are at a higher risk for serious gastrointestinal adverse events due to reduced renal clearance and other factors. Use should be avoided in the last trimester of pregnancy due to risk of premature closure of the fetal ductus arteriosus.
Monitoring Notes: Regulatory documents advise that blood pressure should be closely monitored during the initiation and course of therapy, as the drug can lead to new or worsening hypertension.

Overdose and Emergency Response

Overdose and when to seek help

Category	Official Regulatory Statement
Documented Manifestations	Symptoms of an overdose may include vomiting, nausea, abdominal pain, and epigastric pain. CNS effects such as drowsiness, lethargy, somnolence, and confusion are also documented in regulatory labeling.
Severe Outcomes	Severe or life-threatening manifestations include seizures, coma, acute renal failure, and serious complications like gastrointestinal bleeding or perforation. The risk of these complications is officially noted to be heightened in elderly patients.
Emergency Actions	Immediate medical attention must be sought for signs of severe systemic events, including chest pain, shortness of breath, weakness on one side of the body, or slurred speech. Call the poison control helpline or local emergency number immediately if an overdose is suspected.
Management Principle	No specific antidote is known for this overdose. Management is based on symptomatic and supportive care. Official guidance notes that procedures such as activated charcoal or gastric lavage may be considered for large exposures within a specific timeframe.

The official regulatory profile describes a range of expected clinical presentations, from common gastrointestinal and CNS signs to potentially life-threatening systemic complications. The required emergency actions are explicitly tied to the observation of symptoms indicative of severe compromise. Treatment focuses on mitigating these risks through supportive measures, as procedures like hemodialysis are generally not effective.

Therapeutic Uses of Ketum

What Ketum Treats: Main Uses and Benefits

Ketoprofen may be part of symptomatic management for conditions involving certain distressing symptoms. It is applied across domains where additional symptomatic support is needed, particularly for symptoms related to inflammatory or irritative states. The medication may be part of symptomatic management for conditions presenting with systemic or localized discomfort, which can include: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, sprains, strains, and primary dysmenorrhea.

Supportive Symptomatic Domains

Ketoprofen is generally used across conditions involving episodic or fluctuating manifestations. The drug is relevant for managing symptom clusters that interfere with daily comfort, focusing on pain, stiffness, and localized swelling. The medication provides support that helps ease the overall symptom burden during periods of heightened symptoms. It is also applied across domains where symptoms related to systemic imbalance are present, such as fever, helping to maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Pain, Inflammation, and Fever Ketoprofen helps with managing three primary symptom axes: symptoms related to physical discomfort, symptoms related to inflammatory or irritative states, and symptoms related to heightened physiological activity.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ketum — Official Regulatory Information

The regulatory profile for Ketoprofen defines specific populations for whom use is prohibited or restricted. Use is established for the adult population who have no contraindicating conditions.

Eligibility scope

Classification	Eligibility Status (Regulatory Wording)
Populations for whom use is allowed	Adults without any specified contraindications.
Populations for whom use is not recommended	Pediatric patients (safety/efficacy not established), and breastfeeding mothers.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Ketoprofen/NSAIDs, Aspirin-sensitive asthma, severe heart/renal/hepatic failure, active GI bleeding/ulceration, and during the third trimester of pregnancy.
Age-related eligibility rules	Pediatric use is not established. Geriatric use requires caution and close monitoring.
Condition-specific eligibility rules	Contraindicated in severe organ failure. Restricted in non-severe renal/hepatic impairment and in cardiovascular risk patients.
Pregnancy and lactation eligibility status	Contraindicated in third trimester; restricted/avoided in first two trimesters and during lactation.

Eligibility classifications (high-level)

Eligibility severity classification: Contraindicated, Not Recommended, Restricted/Use with Caution.
Regulatory basis: Based on mandates from global health authorities including FDA and European SmPC documents.
Eligibility-context constraints: The NSAID class effect imposes mandatory cardiovascular and GI risk constraints.

Resulting eligibility structure

Use is strictly contraindicated in severe organ failure, active GI ulceration, and the final trimester of pregnancy.
Safety and effectiveness are not established for the pediatric population (under 18 years).
Patients with renal impairment, hepatic impairment, or cardiovascular risk factors are placed in a restricted use category requiring caution.

The regulatory profile defines eligibility by mandating absolute prohibition in populations with high-risk comorbidities or specific physiological states. Use is permitted primarily for adults who are free from these specific contraindications and who do not require conditional, monitored use based on organ function or pre-existing cardiovascular risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Anticoagulants, Antiplatelet agents (including low-dose Aspirin), other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Oral Corticosteroids, Diuretics, ACE Inhibitors, and SSRIs.
Specific interacting medicines (if explicitly listed)	Lithium, Methotrexate, and Probenecid.
Mechanistic basis of interactions	Pharmacodynamic synergism (increasing GI bleeding risk) and Reduced renal clearance (for Lithium and Methotrexate). Ketoprofen does not induce drug-metabolizing enzymes.
Timing-based interaction rules	No explicit mandatory time-separation windows are documented in the retrieved high-level regulatory snippets.
Population-specific interaction notes	Elderly patients are at greater risk for serious GI events. Volume-depleted and elderly patients are at higher risk of renal failure when co-administered with Diuretics or ACE Inhibitors.
Interaction-related restrictions	Co-administration with Probenecid is not recommended due to significantly reduced Ketoprofen clearance.

Interaction Classifications (High-Level)

Classification	Description
Interaction severity classification	Contraindicated (for peri-operative pain in CABG surgery); Significant/Serious Risk (with anticoagulants, other NSAIDs, corticosteroids); Clinically Significant (with Lithium and Methotrexate).
Interaction-context constraints	Procedural constraint: Contraindicated for peri-operative pain management in the setting of CABG surgery. Substance constraint: Alcohol and tobacco smoking increase the documented risk of serious gastrointestinal adverse effects.

Official Interaction Statements

Co-administration with anticoagulants, antiplatelet agents, and oral corticosteroids creates a synergistic pharmacodynamic effect resulting in a heightened risk of serious gastrointestinal bleeding and ulceration.
Ketoprofen decreases the renal clearance of both Lithium and Methotrexate, resulting in elevated plasma concentrations and increased potential for toxicity of these co-administered agents.
The co-administration of Diuretics or ACE Inhibitors may result in a diminution of the antihypertensive and diuretic efficacy of those agents.
Probenecid reduces the plasma clearance of Ketoprofen, substantially increasing the systemic concentrations of the drug.

Regulatory documents define the product’s interaction structure primarily through two domains: pharmacodynamic reinforcement of bleeding risk, especially within the gastrointestinal tract, and pharmacokinetic modification leading to reduced renal clearance of co-administered drugs like Lithium and Methotrexate. The profile also includes formal restrictions based on a specific procedural context (CABG surgery) and documented risk reinforcement with non-medicinal substances, all of which are documented in official labeling.

Mechanism of Action

The action of Ketoprofen (Ketum) is anchored in the reversible inhibition of the cyclooxygenase ( COX-1 and COX-2) enzymes, which are critical catalysts in the arachidonic acid cascade. By blocking these targets, the drug profoundly reduces the synthesis of pro-inflammatory mediators, primarily prostaglandins ( PGE2), as well as modulating the Lipoxygenase ( LOX) pathway. This molecular interference suppresses the signaling that sensitizes peripheral nociceptors and increases local vascular permeability. The mechanism extends to the central nervous system (CNS), where the drug accesses the hypothalamus. By reducing central PGE2 synthesis, Ketoprofen causes a shift in the hypothalamic temperature set point regulation. The mechanism is physiologically limited by its non-selective nature, which includes blocking the constitutive COX-1 enzyme, thus affecting regulatory processes that rely on homeostatic prostaglandins for gastric mucosal integrity and renal hemodynamics. Furthermore, the drug’s activity is largely confined to the S(+)-enantiomer, a molecular constraint.

Dosage and Administration Information

How to Use Ketum

The administration of Ketum (Ketoprofen) follows standard clinical parameters and depends on the prescribed formulation: systemic use is by the oral route, and local use is by the topical route.

Dosing and Administration

Systemic usage involves Immediate-Release (IR) forms taken multiple times daily or Extended-Release (ER) forms taken once daily. For IR forms, typical adult maintenance doses are 50 mg four times daily or 75 mg three times daily, with a maximum daily dose of 300 mg. The ER form is typically administered as 200 mg once daily. Oral formulations may be taken with food, milk, or antacids to mitigate gastrointestinal effects, and ER forms must be swallowed whole to ensure the intended release characteristics.

Topical application involves administering the gel as approximately 2 to 4 grams (5 to 10 cm of gel) two to four times daily, with a maximum use set at 15 grams per day.

Use Duration and Adjustments

A core procedural instruction is to use the lowest effective dose for the shortest duration necessary for symptomatic management. For non-prescription acute use, treatment duration is typically limited to no more than 10 days.

Dosing is modified for specific patient populations. Older or debilitated adults should be initiated on lower doses. Furthermore, patients with moderate to severe renal or hepatic impairment are subject to maximum daily dose reductions (e.g., 100 mg to 150 mg maximum depending on severity). If an oral dose is missed, the typical procedure is to skip the missed dose if it is near the next scheduled time, and never to take a double dose.

Recent Clinical Evidence

Ketum: Recent Clinical Evidence

Clinical evidence regarding the traditional use of Ketum (also known as Mitragyna speciosa or Kratom) and its primary psychoactive alkaloids, such as mitragynine, is currently limited and mostly exploratory. Ketum is not approved by major regulatory bodies like the FDA or EMA for any medical use.

Research has primarily focused on investigating its potential effects related to pain and opioid withdrawal, though rigorous, large-scale randomized controlled trials (RCTs) are scarce.

Investigational Areas

Studies, often involving individuals with a history of regular Ketum use, have explored its effects in the following areas:

Pain Tolerance: A placebo-controlled, double-blind, within-subject trial investigated the relationship between ingested Ketum and pain tolerance using the cold pressor task. The objective was to evaluate its potential properties related to analgesia.
Opioid Withdrawal Symptoms: Some small studies and case reports have examined the role of Ketum in individuals self-managing symptoms associated with opioid withdrawal. This remains an area of active investigation, with no established therapeutic protocols.
Mood and Anxiety: Observational studies and user reports suggest that Ketum may be associated with self-reported changes in mood and anxiety levels, though these findings are not conclusive and are often confounded by concurrent substance use.

Safety and Dependence

Research has also documented significant safety concerns. Findings across multiple studies and case reports indicate that regular use of Ketum is associated with the potential for physical and psychological dependence, leading to documented withdrawal symptoms upon cessation. The FDA has warned consumers against using Ketum due to the risk of serious adverse events, including liver toxicity, seizures, and substance use disorder.

Frequently Asked Questions (FAQ)

Common questions about Ketum (FAQ)

Q: Is Ketum a type of opioid or a pain reliever?

A: Official documents classify Ketum (Ketoprofen) as a Nonsteroidal Anti-inflammatory Drug (NSAID). This pharmacological class is distinct from opioid analgesics. The medicine is primarily used for its pain-relieving, anti-inflammatory, and fever-reducing effects.

Q: Does Ketum start working right away, or does it take a few days?

A: Ketoprofen is absorbed rapidly into the body after oral administration. For immediate-release forms, the highest drug concentration in the blood is typically reached within 0.5 to 2 hours. This short timeframe is reflective of the drug's rapid absorption characteristics.

Q: Can taking Ketum affect my sleep patterns?

A: Common adverse reactions listed in official documents include somnolence (drowsiness) and dizziness. These Central Nervous System (CNS) effects may impact alertness, which is relevant to sleep patterns.

Q: Is it necessary to avoid certain foods or drinks while using Ketum?

A: Official instructions state that oral formulations may be taken with food, milk, or antacids to help mitigate gastrointestinal effects. Core regulatory documents do not list restrictions on common foods or non-alcoholic beverages.

Q: Do studies suggest Ketum is meant for short-term or long-term use?

A: The standard procedural instruction found in regulatory information is to use the lowest effective dose for the shortest duration necessary for symptomatic management. Furthermore, non-prescription acute use is typically limited to a duration of no more than 10 days.

Q: Can Ketum be taken with alcohol (non-directive question)?

A: Official regulatory documents state that alcohol consumption is known to increase the documented risk of serious gastrointestinal adverse effects. The safety profile documents this heightened risk as a specific constraint.

Q: Can Ketum cause skin sensitivity or rashes?

A: The official safety profile includes the risk of severe skin reactions, such as Stevens-Johnson Syndrome (SJS). For topical forms, official documents also warn of a risk of photosensitization, which is a type of skin reaction when exposed to light or sun.

Q: How long does the effect of one dose of Ketum usually last?

A: The duration of the effect is related to how quickly the drug is eliminated from the body. The elimination half-life for immediate-release forms is relatively short, generally between 0.9 and 3.3 hours.

Q: Is it common to feel tired or dizzy after taking Ketum?

A: Yes, official documents list both dizziness and somnolence (drowsiness or tiredness) as common adverse reactions. This classification confirms they are frequently observed.

Q: What does the latest clinical trial data say about Ketum's purpose?

A: The drug's official purpose is defined by its core effects: analgesic, anti-inflammatory, and antipyretic. Regulatory research summaries note ongoing studies examining its properties in investigational areas, such as related to pain tolerance and opioid withdrawal symptoms.

Q: Why do some patient communities mention a metallic taste with Ketum?

A: Official regulatory documents list taste perversion as an adverse reaction. This is noted as an adverse reaction with an incidence of less than 1% reported in clinical studies.

Q: How quickly does Ketum leave the system after the last dose?

A: Ketoprofen is rapidly eliminated from the body. The elimination half-life for immediate-release forms is typically between 0.9 and 3.3 hours, and the drug is primarily excreted via the kidneys as a metabolite.

Q: Is Ketum known to cause dependence or withdrawal symptoms?

A: Official regulatory documents classify Ketum (Ketoprofen) as a Nonsteroidal Anti-inflammatory Drug (NSAID). This class is not associated with the risks of physical dependence or documented withdrawal symptoms.

Q: Can I use over-the-counter pain relievers while taking Ketum?

A: Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including low-dose Aspirin, is restricted. This is due to a heightened risk of serious gastrointestinal adverse events, such as bleeding or ulceration.

Q: What happens if I miss a scheduled dose of Ketum?

A: Official instructions advise that if a dose is missed and it is near the next scheduled time, the user should skip the missed dose. Regulatory documents state that a double dose must never be taken to compensate for the missed one.

Q: Is Ketum ever prescribed for use in children?

A: Official regulatory documents state that the safety and effectiveness of Ketum (Ketoprofen) have not been established for the pediatric population (patients under 18 years of age).

Q: What are the main differences between the various strengths of Ketum?

A: The different strengths and formulations are specified in regulatory documents based on the formulation type (Immediate-Release vs. Extended-Release) and the patient population. Official guidelines indicate that lower doses may be initiated for certain populations, such as older adults or those with organ impairment.

Q: Is Ketum safe to use while driving or operating machinery?

A: Official warnings list common side effects such as dizziness and somnolence (drowsiness). The presence of these effects indicates that caution is necessary when performing tasks that require full mental alertness.

Q: What common blood tests might be affected by Ketum?

A: The drug is known to have effects on platelet function, which is measured in blood tests related to clotting. Due to warnings concerning severe renal and hepatic impairment, the drug may also affect associated liver and kidney function tests.

Q: Are there any reports of Ketum causing confusion or memory issues?

A: Regulatory information related to accidental overdose or severe intoxication includes symptoms such as confusion and profound drowsiness. These are not listed as common side effects at the prescribed dose level.

Q: Is Ketum considered a preventative medicine or a treatment?

A: The drug is officially indicated for the symptomatic management of conditions. This means its intended use is to address and alleviate existing symptoms like pain and inflammation, rather than preventing the onset of an underlying disease.

Q: What happens if I accidentally take more Ketum than described?

A: An accidental overdose can result in symptoms such as drowsiness, confusion, dizziness, and the potential for serious gastrointestinal bleeding. These situations are noted to warrant immediate medical attention.

Q: Does Ketum come in different forms, such as liquid or injection?

A: Official regulatory documents list the forms available for human use as capsules, tablets, topical gels, and patches. The standard forms approved for general use do not include a liquid or injectable product.

Q: Why is the drug’s purpose sometimes described as 'symptomatic relief'?

A: The term symptomatic relief means the medicine works to address and reduce the visible or felt symptoms of a condition, such as pain, swelling, and fever. The drug does not cure the underlying cause of the disease.

Q: What are the official discontinuation instructions for Ketum?

A: Official regulatory documents instruct users to stop use immediately if an allergic reaction or certain severe skin reactions occur. For acute topical use, discontinuation is advised if symptoms persist beyond a set number of days.

Q: Does Ketum interact with common antacids or acid reflux medicines?

A: Regulatory text states that the oral form may be taken with antacids to help reduce gastrointestinal effects. While formal interactions with other specific acid reflux medicines (such as H2 blockers or PPIs) are not detailed in the core documents, antacids are permissible.

How should Ketum be stored and disposed of?

How to Store and Dispose of Ketum (Ketoprofen)

Official regulatory guidelines specify distinct storage and disposal requirements for Ketoprofen products.

Oral capsules must be stored at Controlled Room Temperature (20 C to 25 C) and kept away from excessive heat, light, and moisture. Storage must prevent freezing. The medicine must be dispensed in a tight container with a child-resistant closure.

For topical gels, storage often requires keeping the product below 25 C and away from naked flames. Once opened, some gels must be used within one month. All forms must be securely stored out of the sight and reach of children.

Disposal instructions state that unused or expired medicine should not be thrown away via wastewater or household waste. The user is instructed to consult a pharmacist or healthcare professional for the correct disposal method.

Ketum